Artemisinin Combination Therapy Market 2027 By Type, Distribution Channels and Geography | The Insight Partners

Artemisinin Combination Therapy Market to 2027 - Global Analysis and Forecasts By Type (Artemether-Lumefantrine, Artesunate-Amodiaquine, Dihydroartemisinin-Piperaquine, Artesunate-Mefloquine, Artesunate-Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate); Distribution Channels (Retail pharmacy, Hospitals, Others) and Geography

Report Code: TIPRE00004761 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Artemisinin combination therapy used to treatment of malaria disease. Malaria is a serious, life threatening disease spread by mosquitoes & causes by a parasite which mainly destroy red blood cell in the body. The artemiisinin combination therapy work with partner drug. The artemisinin compound play important role in reduction of no. of parasites during the 1st three days of treatment (reduction of parasite biomass) and the role of partner drug is to eliminate the remaining parasite. The artemisinin is a drug derived from the Asian plant Artemisia annua.

MARKET DYNAMICS
The artemisinin combination therapy market is expected to grow during the forecast period owing to the key driving factors such as rising demand for artemisinin combination therapy, increasing pollution related problems, the various government initiatives for malaria disease awareness. In addition, various players in the emerging market have strong pipeline product and high potential which are anticipated to create several growth opportunities for the market during the forecast period.

MARKET SCOPE
The "Global Artemisinin Combination Therapy Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of artemisinin combination therapy with detailed market segmentation by type, distribution channel and geography. The global artemisinin combination therapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading the artemisinin combination therapy market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global artemisinin combination therapy market is segmented on the basis of type and distribution channels. Based on type, the market is segmented as artemether-lumefantrine, Artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine and pyronaridine-artesunate. On the basis of distribution channel the global artemisinin combination therapy market is classify into retail pharmacy, hospitals and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global artemisinin combination therapy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The artemisinin combination therapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting artemisinin combination therapy market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the artemisinin combination therapy market in these regions.

MARKET PLAYERS
The reports cover key developments in the artemisinin combination therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from artemisinin combination therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for artemisinin combination therapy market in the global market. Below mentioned is the list of few companies engaged in the artemisinin combination therapy market.

The report also includes the profiles of key artemisinin combination therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Hovid-Integrated Global Pharmaceutical Partner
  • Ipca Laboratories Ltd
  • Aspen Holdings
  • AJANTA PHARMA
  • Novartis AG
  • Sanofi
  • Cipla Inc
  • KPC Pharmaceuticals
  • Mylan N.V
  • Calyx Chemicals and Pharmaceuticals Limited
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Artemisinin Combination Therapy Market - By Type
1.3.2 Artemisinin Combination Therapy Market - By Distribution Channels
1.3.3 Artemisinin Combination Therapy Market - By Region
1.3.3.1 by Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ARTEMISININ COMBINATION THERAPY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ARTEMISININ COMBINATION THERAPY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ARTEMISININ COMBINATION THERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1. ARTEMISININ COMBINATION THERAPY - GLOBAL MARKET OVERVIEW
6.2. ARTEMISININ COMBINATION THERAPY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ARTEMISININ COMBINATION THERAPY MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. ARTEMETHER-LUMEFANTRINE
7.3.1. Overview
7.3.2. Artemether-Lumefantrine Market Forecast and Analysis
7.4. ARTESUNATE-AMODIAQUINE
7.4.1. Overview
7.4.2. Artesunate-Amodiaquine Market Forecast and Analysis
7.5. DIHYDROARTEMISININ-PIPERAQUINE
7.5.1. Overview
7.5.2. Dihydroartemisinin-Piperaquine Market Forecast and Analysis
7.6. ARTESUNATE-MEFLOQUINE
7.6.1. Overview
7.6.2. Artesunate-Mefloquine Market Forecast and Analysis
7.7. ARTESUNATE-SULFADOXINE-PYRIMETHAMINE
7.7.1. Overview
7.7.2. Artesunate-Sulfadoxine-Pyrimethamine Market Forecast and Analysis
7.8. PYRONARIDINE-ARTESUNATE
7.8.1. Overview
7.8.2. Pyronaridine-Artesunate Market Forecast and Analysis
8. ARTEMISININ COMBINATION THERAPY MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNELS
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNELS MARKET FORECASTS AND ANALYSIS
8.3. RETAIL PHARMACY
8.3.1. Overview
8.3.2. Retail pharmacy Market Forecast and Analysis
8.4. HOSPITALS
8.4.1. Overview
8.4.2. Hospitals Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ARTEMISININ COMBINATION THERAPY MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Artemisinin Combination Therapy Market Overview
9.1.2 North America Artemisinin Combination Therapy Market Forecasts and Analysis
9.1.3 North America Artemisinin Combination Therapy Market Forecasts and Analysis - By Type
9.1.4 North America Artemisinin Combination Therapy Market Forecasts and Analysis - By Distribution Channels
9.1.5 North America Artemisinin Combination Therapy Market Forecasts and Analysis - By Countries
9.1.5.1 United States Artemisinin Combination Therapy Market
9.1.5.1.1 United States Artemisinin Combination Therapy Market by Type
9.1.5.1.2 United States Artemisinin Combination Therapy Market by Distribution Channels
9.1.5.2 Canada Artemisinin Combination Therapy Market
9.1.5.2.1 Canada Artemisinin Combination Therapy Market by Type
9.1.5.2.2 Canada Artemisinin Combination Therapy Market by Distribution Channels
9.1.5.3 Mexico Artemisinin Combination Therapy Market
9.1.5.3.1 Mexico Artemisinin Combination Therapy Market by Type
9.1.5.3.2 Mexico Artemisinin Combination Therapy Market by Distribution Channels
9.2. EUROPE
9.2.1 Europe Artemisinin Combination Therapy Market Overview
9.2.2 Europe Artemisinin Combination Therapy Market Forecasts and Analysis
9.2.3 Europe Artemisinin Combination Therapy Market Forecasts and Analysis - By Type
9.2.4 Europe Artemisinin Combination Therapy Market Forecasts and Analysis - By Distribution Channels
9.2.5 Europe Artemisinin Combination Therapy Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Artemisinin Combination Therapy Market
9.2.5.1.1 Germany Artemisinin Combination Therapy Market by Type
9.2.5.1.2 Germany Artemisinin Combination Therapy Market by Distribution Channels
9.2.5.2 France Artemisinin Combination Therapy Market
9.2.5.2.1 France Artemisinin Combination Therapy Market by Type
9.2.5.2.2 France Artemisinin Combination Therapy Market by Distribution Channels
9.2.5.3 Italy Artemisinin Combination Therapy Market
9.2.5.3.1 Italy Artemisinin Combination Therapy Market by Type
9.2.5.3.2 Italy Artemisinin Combination Therapy Market by Distribution Channels
9.2.5.4 Spain Artemisinin Combination Therapy Market
9.2.5.4.1 Spain Artemisinin Combination Therapy Market by Type
9.2.5.4.2 Spain Artemisinin Combination Therapy Market by Distribution Channels
9.2.5.5 United Kingdom Artemisinin Combination Therapy Market
9.2.5.5.1 United Kingdom Artemisinin Combination Therapy Market by Type
9.2.5.5.2 United Kingdom Artemisinin Combination Therapy Market by Distribution Channels
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Artemisinin Combination Therapy Market Overview
9.3.2 Asia-Pacific Artemisinin Combination Therapy Market Forecasts and Analysis
9.3.3 Asia-Pacific Artemisinin Combination Therapy Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Artemisinin Combination Therapy Market Forecasts and Analysis - By Distribution Channels
9.3.5 Asia-Pacific Artemisinin Combination Therapy Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Artemisinin Combination Therapy Market
9.3.5.1.1 Australia Artemisinin Combination Therapy Market by Type
9.3.5.1.2 Australia Artemisinin Combination Therapy Market by Distribution Channels
9.3.5.2 China Artemisinin Combination Therapy Market
9.3.5.2.1 China Artemisinin Combination Therapy Market by Type
9.3.5.2.2 China Artemisinin Combination Therapy Market by Distribution Channels
9.3.5.3 India Artemisinin Combination Therapy Market
9.3.5.3.1 India Artemisinin Combination Therapy Market by Type
9.3.5.3.2 India Artemisinin Combination Therapy Market by Distribution Channels
9.3.5.4 Japan Artemisinin Combination Therapy Market
9.3.5.4.1 Japan Artemisinin Combination Therapy Market by Type
9.3.5.4.2 Japan Artemisinin Combination Therapy Market by Distribution Channels
9.3.5.5 South Korea Artemisinin Combination Therapy Market
9.3.5.5.1 South Korea Artemisinin Combination Therapy Market by Type
9.3.5.5.2 South Korea Artemisinin Combination Therapy Market by Distribution Channels
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Artemisinin Combination Therapy Market Overview
9.4.2 Middle East and Africa Artemisinin Combination Therapy Market Forecasts and Analysis
9.4.3 Middle East and Africa Artemisinin Combination Therapy Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Artemisinin Combination Therapy Market Forecasts and Analysis - By Distribution Channels
9.4.5 Middle East and Africa Artemisinin Combination Therapy Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Artemisinin Combination Therapy Market
9.4.5.1.1 South Africa Artemisinin Combination Therapy Market by Type
9.4.5.1.2 South Africa Artemisinin Combination Therapy Market by Distribution Channels
9.4.5.2 Saudi Arabia Artemisinin Combination Therapy Market
9.4.5.2.1 Saudi Arabia Artemisinin Combination Therapy Market by Type
9.4.5.2.2 Saudi Arabia Artemisinin Combination Therapy Market by Distribution Channels
9.4.5.3 U.A.E Artemisinin Combination Therapy Market
9.4.5.3.1 U.A.E Artemisinin Combination Therapy Market by Type
9.4.5.3.2 U.A.E Artemisinin Combination Therapy Market by Distribution Channels
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Artemisinin Combination Therapy Market Overview
9.5.2 South and Central America Artemisinin Combination Therapy Market Forecasts and Analysis
9.5.3 South and Central America Artemisinin Combination Therapy Market Forecasts and Analysis - By Type
9.5.4 South and Central America Artemisinin Combination Therapy Market Forecasts and Analysis - By Distribution Channels
9.5.5 South and Central America Artemisinin Combination Therapy Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Artemisinin Combination Therapy Market
9.5.5.1.1 Brazil Artemisinin Combination Therapy Market by Type
9.5.5.1.2 Brazil Artemisinin Combination Therapy Market by Distribution Channels
9.5.5.2 Argentina Artemisinin Combination Therapy Market
9.5.5.2.1 Argentina Artemisinin Combination Therapy Market by Type
9.5.5.2.2 Argentina Artemisinin Combination Therapy Market by Distribution Channels
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ARTEMISININ COMBINATION THERAPY MARKET, KEY COMPANY PROFILES
11.1. HOVID-INTEGRATED GLOBAL PHARMACEUTICAL PARTNER
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. IPCA LABORATORIES LTD
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ASPEN HOLDINGS
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. AJANTA PHARMA
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. NOVARTIS AG
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SANOFI
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. CIPLA INC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. KPC PHARMACEUTICALS
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. MYLAN N.V
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LTD
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Hovid-Integrated Global Pharmaceutical Partner
2. Ipca Laboratories Ltd
3. Aspen Holdings
4. AJANTA PHARMA
5. Novartis AG
6. Sanofi
7. Cipla Inc
8. KPC Pharmaceuticals
9. Mylan N.V
10. Sun Pharmaceutical Industries Ltd